Abstract | BACKGROUND: METHODS: In this prospective, observational study on 18 patients, we assessed symptom severity before therapy, after 15 days, 1, 3 and 6 months' follow-up with the sweating- flushing-itch- paresthesia- pain (SFIPP) Frey scale specifically designed by the authors themselves for this study. RESULTS: CONCLUSIONS: The prevalence of "unusual" manifestations is not negligible. BoNT-A improves symptoms severity. The SFIPP-Frey scale may be useful to assess symptoms and to monitor post- therapy outcomes.
|
Authors | Maria Raffaella Marchese, Francesco Bussu, Stefano Settimi, Emanuele Scarano, Giovanni Almadori, Jacopo Galli |
Journal | Head & neck
(Head Neck)
Vol. 43
Issue 3
Pg. 949-955
(03 2021)
ISSN: 1097-0347 [Electronic] United States |
PMID | 33247501
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2020 Wiley Periodicals LLC. |
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Botulinum Toxins, Type A
(therapeutic use)
- Humans
- Injections
- Neuromuscular Agents
(therapeutic use)
- Parotid Gland
- Postoperative Complications
- Prospective Studies
- Sweating, Gustatory
(diagnosis, drug therapy)
|